Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Major Program
NCI Community Oncology Research Program
Supportive Care and Symptom Management
Research Group
Community Oncology and Prevention Trials
University of Rochester NCORP Research Base
Recruiting ID
For more information, see NCT03367572
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and
dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron
hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in
patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may
help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Breast Carcinoma
Luke Peppone, Bryan A. Faller, Brian L. Burnette

See list of participating sites